Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145884 · ClinicalTrials.gov registry record · Phase 2
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
A Phase 2 study of Hemangioma, sponsored by Rady Children's Hospital, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02145884: Completed Phase 2 study of Hemangioma, sponsored by Rady Children's Hospital, San Diego.
NCT02145884 is a Phase 2 study of Hemangioma that has completed, run by Rady Children's Hospital, San Diego. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02145884, a Phase 2 study of Hemangioma, has completed, sponsored by Rady Children's Hospital, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas.
Primary Outcome
At each visit, the size of the IH is assessed in three dimensions (length, width, and height) in cm.
Conditions Studied
Interventions
- DRUG timolol maleate 0.5% gel
Study Locations (1)
California
- Pediatric and Adolescent Dermatology, Rady Children's Hospital/University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02145884 record still lists
NCT02145884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Hemangioma appearing as the primary indexed condition, and to 1 intervention - of which timolol maleate 0.5% gel is the first listed.
NCT02145884 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02145884 about?
NCT02145884 is a clinical study titled "Topical Timolol Gel for the Treatment of Infantile Hemangiomas". We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas...
What is the current status of trial NCT02145884?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-05. Estimated completion is 2016-11.
What conditions does trial NCT02145884 study?
This clinical trial studies the following conditions: Hemangioma.
What interventions are being tested in trial NCT02145884?
The interventions under investigation include: timolol maleate 0.5% gel (DRUG).
Who is sponsoring clinical trial NCT02145884?
This trial is sponsored by Rady Children's Hospital, San Diego, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02145884 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemangioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02145884's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia